Location of Repository

Alpha7 Nicotinic Acetylcholine Receptor Is a Target in Pharmacology and Toxicology

By Miroslav Pohanka


Alpha7 nicotinic acetylcholine receptor (α7 nAChR) is an important part of the cholinergic nerve system in the brain. Moreover, it is associated with a cholinergic anti-inflammatory pathway in the termination of the parasympathetic nervous system. Antagonists of α7 nAChR are a wide group represented by conotoxin and bungarotoxin. Even Alzheimer’s disease drug memantine acting as an antagonist in its side pathway belongs in this group. Agonists of α7 nAChR are suitable for treatment of multiple cognitive dysfunctions such as Alzheimer’s disease or schizophrenia. Inflammation or even sepsis can be ameliorated by the agonistic acting compounds. Preparations RG3487, SEN34625/WYE-103914, SEN12333, ABT-107, Clozapine, GTS-21, CNI-1493, and AR-R17779 are representative examples of the novel compounds with affinity toward the α7 nAChR. Pharmacological, toxicological, and medicinal significance of α7 nAChR are discussed throughout this paper

Topics: Review
Publisher: Molecular Diversity Preservation International (MDPI)
OAI identifier: oai:pubmedcentral.nih.gov:3292018
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles



    1. (2000). 125I-alpha-conotoxin MII identifies a novel nicotinic acetylcholine receptor population in mouse brain.
    2. (2009). A cog in cognition: How the alpha 7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits.
    3. (2000). A comparative non-radioactive in situ hybridization and immunohistochemical study of the distribution of alpha7 and alpha8 subunits of the nicotinic acetylcholine receptors in visual areas of the chick brain. Brain Res.
    4. (2006). A novel inhibitor of inflammatory cytokine production (CNI-1493) reduces rodent post-hemorrhagic vasospasm. Neurocit. Care
    5. (2001). A quick guide to muscarinic acetylcholine receptors.
    6. (2010). A randomised placebo-controlled multicentre trial of intravenous semapimod HCl for moderate to severe Crohn’s disease. Gut
    7. (2009). A review of experimental techniques used for the heterologous expression of nicotinic acetylcholine receptors.
    8. (2008). Acetylcholine beyond neurons: The non-neuronal cholinergic system in humans.
    9. (2005). Acetylcholine release from the central nervous system: A 50year retrospective.
    10. (2010). Activation of functional α7-containing nAChRs in hippocampal CA1 pyrmidal neurons by physiologica levels of choline in the presence of PNU-120596. PLoS One
    11. (2011). Activation of nicotinic α(7) acetylcholine receptor enhances long term potentation in wild type mice but not
    12. (2007). Activation of the cholinergic anti-inflammatory pathway ameliorates postoperative ileus in mice. Gastroenterology
    13. (2009). Airway management in trauma. Minerva Anestesiol.
    14. (2007). Allosteric modulation of nicotinic acetlycholine receptors.
    15. (2004). Alpha-7 nicotinic receptor agonists: Potential new candidates for the treatment of schizophrenia. Psychopharmacology
    16. (2009). Alpha-conotoxins as pharmacological probes of nicotinic acetylholine receptors. Acta Pharmacol.
    17. (2009). Alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex.
    18. (2007). Amperometric biosensor for evaluation of competitive cholinesterase inhibition by the reactivation HI-6.
    19. (2004). AR-R 17779 improves social recognition in rats by activation of nicotinic alpha7 receptors. Psychopharmacology
    20. (2009). Association between a genetic variant of the alpha-7 nicotinic acetylcholine receptor subunit and four types of dementia.
    21. (2009). Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 redceptor knockout mice.
    22. (2005). Beta2 subunit contribution to 4/7 alpha-conotoxin binding to the nicotinic acetylchline receptor.
    23. (1999). Biochemical characterization and nuclear magnetic resonance structure of novel alpha-conotoxins isolated from the venom of conus consors. Biochemistry
    24. (2006). Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting.
    25. (2006). Bradycardia and hypotension refractory to ephedrine and atropine treatment: Severe autonomic dysfunction with abnormal heart rate variability. Acta Anaesthesiol. Taiwan
    26. (1997). Choline is a selective agonist of alpha7 nicotnic acetylcholine receptors in the rat brain neurons.
    27. (2005). Choline transporters, cholinergic transmission and cognition.
    28. (2010). Cholinergic anti-inflammatory pathway: A possible approach to protect against myocardial ischemia reperfusion injury.
    29. (2009). Cholinergic control of inflammation.
    30. (2010). Cholinergic modulation of neuronal excitability in the rat suprachiasmatic nucleus.
    31. (2011). Cholinesterases, a target of pharmacology and toxicology.
    32. (2010). Clozapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst. Rev.
    33. (2008). CNI-1493 inhibits Abeta production, and cognitive deterioration in an animal model of Alzheimer’s disease.
    34. Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: From animal models to human pathophysiology.
    35. (2005). Comments on “Memantine blocks alpha7* nicotnic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons”.
    36. (2005). Contribution of a snake venom toxin to myasthenia gravis: The discovery of alpha-bungarotoxin in
    37. (2007). Contribution of carrier-mediated transport system to the blood-brain barrier as a supporting and protecting interface for the brain, importance for CNS drug discovery and
    38. (1998). Crystal structure of botulinum neurotoxin type A and implications for toxicity.
    39. (2003). Cytosolic choline acetyltransferase binds specifically to cholinergic plasma membrane of rat brain synaptosomes to generate membrane-bound enzyme.
    40. (2009). Deletion of the alpha 7 nicotinic acetylcholine receptor gene improves cognitive deficits and synaptic pathology in a mouse model of Alzheimer’s disease.
    41. (2006). Differential effects of the muscarinic M1 receptor agonist RS-86 and the acetylcholine-esterase inhibitor donepezil on REM sleep regulation in healthy volunteers. Neuropsychopharmacology
    42. (2011). Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia.
    43. (2008). Experimental therapeutic strategies for severe sepsis: Mediators and mechanisms.
    44. (2003). Expression and localization of acetylcholinesterase at the neuromuscular junction.
    45. (2005). Fat meets the cholinergic antiinflammatory pathway.
    46. (2008). From CNI-1493 to the immunological homunculus: Physiology of the inflammatory reflex.
    47. (2011). From toxins targeting ligand gated ion channels to therapeutic molecules. Toxins
    48. Human platelets express functional alpha 7-nicotinic acetylcholine receptors.
    49. (2003). Human α4β2 acetylcholine receptors formed from linked subunits.
    50. Hypersensitive knockin mouse strains identify receptors and pathways for nicotine action.
    51. (2011). Implementing a collaborative protocol in a sepsis intervention program: Lessons learned. Lung
    52. In vitro phramacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
    53. (2005). Increased alpha 7 nicotinic acetylcholine receptor protein levels in Alzheimer’s disease patients.
    54. (1985). Isolation of an organism resembling Clostridium baratii which produces type F botulinal toxon from an infant with botulism.
    55. (2010). Kinetics of M1 muscarinic receptor and G protein signaling to phospholipase C in living cells.
    56. (2011). Lipophilicity and its relationship with passive drug permeation.
    57. (2000). Localization of agonist and competitive antagonist binding sites on nicotinic acetylcholine receptors.
    58. (1999). Looking back on the discovery of alpha-bungarotoxin.
    59. (2000). Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice.
    60. (2010). Macrophage signaling in HIV-1 infection. Retrovirology
    61. Macrophage-assisted inflammation and pharmacological regulation of the cholinergic anti-inflammatory pathway.
    62. (2009). Malignant hyperthermia and muscular dystrophies.
    63. (2009). Mammalian nicotinic acetylcholine receptors: From structure to function.
    64. (2005). Memantine blocks alpha7* nicotnic acetylcholine receptors more potently than N-methyl-D-aspartate receptors in rat hippocampal neurons.
    65. Modulation of ionising radiation generated oxidative stress by HI-6 (asoxime) in a laboratory rat model.
    66. (2010). Modulation of tularemia disease progress by the bisquaternary pyridinium oxime HI-6. Acta Vet.
    67. (1995). Muscarinic acetylcholine receptors: Signal transduction through multiple effectors.
    68. (2008). Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr.
    69. (2009). Muscarinic receptor subtypes in the alimentary track.
    70. (1999). Mutational analysis of the charge selectivity filter of the α7 nicotinic acetylcholine receptor. Neuron
    71. (2001). Neuronal nicotinic acetylcholine receptor subunit knockout mice: Physiological and behavioral phenotypes and possible clinical inplications.
    72. Nicotine inhibits tumor necrosis factor-alpha induced IL-6 and IL-8 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis.
    73. nicotinic acetylcholine receptor agonist GTS-21 attenuates ventilator-induced tumour necrosis factor-α production and lung injury.
    74. Nicotinic receptors: Allosteric transitions and therapeutic targets in the nervous system.
    75. (2007). Oral absorption and in vivo biodistribution of alpha-conotoxin MII and a lipidic analogue.
    76. (2007). Physiology and immunolgy of the cholinergic antiinflammatory pathway.
    77. (2007). Pretreating rats with parenteral ophthalmic antimuscarinic agents decreases mortality from lethal organophosphate poisoning.
    78. (2009). Procognitive and neuroprotective activity of novel alpha 7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive
    79. (2002). Professor Chen-Yuan Lee, MD (1915–2001), pharmacologist: Snake venom research at the
    80. (2009). Protein complexes in snake venom.
    81. (2011). receptor stimulation decreases pancreatitis severity in rats by activation of the cholinergic anti-inflammatory pathway. Crit. Care Med.
    82. (1992). Reconstitution of agonist-stimulated phoshpatidylinostiol 4,5-bisphosphate hydrolysis using purified m1 muscarinic receptor,
    83. (1991). Reconstitutively active G protein-coupled receptors purified from baculovirus-infected insect cells.
    84. (2005). Refined Structure of the nicotinic acetylcholine receptor at 4 A resolution.
    85. Reflex control of immunity.
    86. (2003). Relative level of cytoprotection produced by analogs of choline and the role of alpha 7-nicotinic acetylcholine receptors. Synapse
    87. (2002). Review of oximes in the antidotal treatment of poisoning by organophoshorus nerve agents.
    88. (2011). RG3487, a novel nicotinic alpha7 receptor partial agonist, improves cognition and sensorimotor gating in rodents.
    89. (2009). Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes.
    90. (2007). Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit. Care Med.
    91. (1999). Single amino acid substitutions in alpha-conotoxin PnIA shift selectivity for subtypes of the mammalian neuronal nicotinic acetylcholine receptor.
    92. (2005). Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport system. NeuroRx
    93. (2006). SNARE complex regulation by phosphorylation.
    94. (2004). Structure-activity relationships of alpha-conotoxins targeting neuronal nicotinic acetylcholine receptors.
    95. (1995). Synaptic like microvesicles: Do they participate in regulated exocytosis?
    96. Synergism in survival to endotoxic shock in rats given microencapsulated CNI-1493 and antisense oligomers to NF-kappaB.
    97. (2008). TC-5214 (S-()-mecamylamine): A neuronal nicotinic receptor modulator with antidepressant activity.
    98. (2009). TC-5619: An alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia.
    99. (2010). The antipsychotic potential of muscarinic allosteric modulation. Drug News Perspect.
    100. (2006). The cholinergic antagonist alpha-bungarotoxin also binds and blocks a subset of GABA receptors.
    101. (2008). The effect of HI-6 on cholinesterases and on the cholinergic system of the rat bladder.
    102. (2002). The inflammatory reflex.
    103. (2002). The levels of norharman are high enough after smoking to affect monoamineoxidase B in platelets.
    104. (2002). The nicotinic allosteric potentiating ligand galantamine facilitates synaptic transmission in the mammalian central nervous system.
    105. (2009). The selective alpha7 agonist GTS-21 attenuates cytokine production in human whole blood and human monocytes activated by ligands for TLR2, TLR3, TLR4, TLR9, and
    106. (2010). The t-SNARE complex: A close up.
    107. (2006). Transdermal scopolamine for prevention of motion sickness: Clinical pharmacokinetics and therapeutic applications.
    108. (1986). Two cases of type infant botulism caused by neurotoxigenic clostridium butyricum in
    109. (2007). Two novel mutations in the BChE gene in patients with prolonged duration of action of mivacurium or succinylcholine during anaesthesia. Pharmacogenet. Genomics
    110. (1998). Two opposite signal transducting mechanisms regulate a G-protein-coupled guanylyl cyclase.
    111. (2008). Use of caffeine and nicotine in people with schizophrenia. Curr. Drug Abuse Rev.
    112. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature
    113. (2010). Why do patients with schizophrenia smoke.
    114. (2012). WormBook 2007, doi:10.1895/wormbook.1.131.1. Available online: http://www.wormbook.org (accessed on 17

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.